User login
Key clinical point: Enzalutamide improves outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) in a prospective real-world study.
Major finding: The median time to treatment failure in chemotherapy and abiraterone-naïve patients was 12.9 months and those who were previously treated with chemotherapy and were abiraterone naïve was 8.4 months.
Study details: A prospective, observational PREMISE study of 1,732 patients with mCRPC who received enzalutamide.
Disclosures: This study was sponsored by Astellas Pharma Inc. The authors received honoraria, travel funds, grants, consulting/personal fees, and financial and nonfinancial support from various sources. Some authors reported being employed by an organization/foundation that receives funding from various private and public sector sources.
Source: Payne H et al. Int J Cancer. 2021 Oct 14. doi: 10.1002/ijc.33845.
Key clinical point: Enzalutamide improves outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) in a prospective real-world study.
Major finding: The median time to treatment failure in chemotherapy and abiraterone-naïve patients was 12.9 months and those who were previously treated with chemotherapy and were abiraterone naïve was 8.4 months.
Study details: A prospective, observational PREMISE study of 1,732 patients with mCRPC who received enzalutamide.
Disclosures: This study was sponsored by Astellas Pharma Inc. The authors received honoraria, travel funds, grants, consulting/personal fees, and financial and nonfinancial support from various sources. Some authors reported being employed by an organization/foundation that receives funding from various private and public sector sources.
Source: Payne H et al. Int J Cancer. 2021 Oct 14. doi: 10.1002/ijc.33845.
Key clinical point: Enzalutamide improves outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) in a prospective real-world study.
Major finding: The median time to treatment failure in chemotherapy and abiraterone-naïve patients was 12.9 months and those who were previously treated with chemotherapy and were abiraterone naïve was 8.4 months.
Study details: A prospective, observational PREMISE study of 1,732 patients with mCRPC who received enzalutamide.
Disclosures: This study was sponsored by Astellas Pharma Inc. The authors received honoraria, travel funds, grants, consulting/personal fees, and financial and nonfinancial support from various sources. Some authors reported being employed by an organization/foundation that receives funding from various private and public sector sources.
Source: Payne H et al. Int J Cancer. 2021 Oct 14. doi: 10.1002/ijc.33845.